Recurrent Digestive System Neuroendocrine Tumor G1
5 clinical trials · Condition
◉ Watch Recurrent Digestive System Neuroendocrine Tumor G1
| Record | Firm | Date |
|---|---|---|
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors (NCT01841736) | National Cancer Institute (NCI) | 2013-09-20 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01548482) | National Cancer Institute (NCI) | 2012-03-01 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (NCT01204476) | National Cancer Institute (NCI) | 2010-10-01 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (NCT01010126) | National Cancer Institute (NCI) | 2009-09-08 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer (NCT00454363) | National Cancer Institute (NCI) | 2007-03-01 |
Track Recurrent Digestive System Neuroendocrine Tumor G1 automatically
Every clearance here is in the API, with alerts when new ones post.